<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-001409
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20020521
<ITEMS>5
<ITEMS>7
<FILING-DATE>20020521
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02658708
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v81918e8-k.htm
<DESCRIPTION>ADVANCED BIOTHERAPY FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="3"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="3"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="3"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15</B>(d) <B>of the Securities Exchange Act of 1934</B></FONT>

<P align="left"><FONT size="2">Date of Report (Date of earliest
reported) <U>May&nbsp;21, 2002</U></FONT>

<P align="center"><FONT size="2">Advanced Biotherapy, Inc.</FONT>

<HR width="26%" align="center" size="1" noshade>

<DIV align="center"><FONT size="2"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></FONT></DIV>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="95%">
<TR valign="bottom">
        <TD width="34%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Delaware</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
0-26323
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">95-0402415</FONT></DIV></TD>
</TR>
<TR>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
<HR size="1" noshade>
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">(State or other jurisdiction<BR>
of incorporation)</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
(Commission<BR>
File Number)
</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">(IRS Employer<BR>
Identification No.)</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="95%">
<TR valign="bottom">
        <TD width="51%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="21%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="22%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>
Woodland Hills, California</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="bottom"><FONT size="2">91367</FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><HR size="1" noshade></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="right" valign="top"><FONT size="2">
<HR size="1" noshade></FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">(Address of principal executive offices)</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap valign="top"><FONT size="2">(Zip Code)</FONT></TD>
        <TD align="right" valign="top"><FONT size="2"></FONT></TD>
</TR>
</TABLE>
</CENTER>
<P><FONT size="2">Registrant&#146;s telephone number, including area code <U>(818)&nbsp;883-6716</U>
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v81918ex99-1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on May&nbsp;20, 2002, which announced
that it has a patent application pending for the exclusive use of any form of
antibody to gamma interferon (IFN-g) for the treatment of Chrohn&#146;s Disease. A
copy of such press release is incorporated herein by reference and is attached
as an exhibit to this Form&nbsp;8-K.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
   <TD width="1%" align="right" nowrap><FONT size="2">(c)</FONT></TD>
   <TD width="1%" nowrap><FONT size="2">&nbsp;&nbsp;</FONT></TD>
   <TD width="98%"><FONT size="2">Exhibits.</FONT></TD>
</TR>
</TABLE>

<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="12%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="83%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="left"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Press Release, dated May&nbsp;20, 2002</FONT></TD>
</TR>
</TABLE>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="50%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="top">
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD colspan="2"><FONT size="2">ADVANCED BIOTHERAPY, INC.<br>
(Registrant)</FONT></TD>
</TR>

<TR><TD>&nbsp;<BR>&nbsp;</TD></TR>
<TR valign="top">
        <TD><FONT size="2">Date: May&nbsp;20, 2002</FONT></TD>
        <TD><FONT size="2">By:&nbsp;</FONT></TD>
        <TD align="left"><FONT size="2">/s/Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD colspan="2"><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade color="#000000"></TD>
</TR>
<TR valign="top">
        <TD colspan="2">&nbsp;</TD>
        <TD><FONT size="2">Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>

<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="10%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="85%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated May&nbsp;20, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v81918ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P><FONT size="2">EXHIBIT 99.1
</FONT>
<P align="left"><FONT size="2"><B>Advanced Biotherapy, Inc. Discloses Method of Use Patent Pending for Antibodies
to Gamma Interferon in the Treatment of Crohn&#146;s Disease</B></FONT>

<P><FONT size="2">WOODLAND HILLS, Calif.&#151; (BW HealthWire)&#151; May&nbsp;20, 2002&#151; Advanced Biotherapy,
Inc.(OTCBB: ADVB &#151; news) announced today that it has a patent application
pending for the exclusive use of any form of antibody to gamma interferon
(IFN-g) for the treatment of Crohn&#146;s Disease. As previously reported, The
United States Patent and Trademark Office (USPTO)&nbsp;issued U.S. Patent No.
6,333,032 to the Company for the exclusive use of IFN-g antibodies &#151; including
humanized and fully human, as well as other antibody types &#151; to treat Multiple
Sclerosis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic
Arthritis (a form of psoriasis) and Ankylosing Spondylitis.
</FONT>
<P><FONT size="2">Commenting on this announcement, Mr.&nbsp;Edmond Buccellato, President and Chief
Executive Officer, stated, &#147;This important pending patent application greatly
enhances our patent portfolio which covers treatment of several autoimmune
diseases, including this very devastating disease, using IFN-g antibodies.&#148;
</FONT>
<P><FONT size="2">Crohn&#146;s disease is a form of inflammatory bowel disease (IBD)&nbsp;that may affect
any part of the digestive tract. The cause is unknown, but it appears to be, in
part, an autoimmune disease. IFN-g is important in the normal immune system,
and its hyperproduction may help trigger autoimmune processes. Increased
production of IFN-g has already been confirmed in inflammatory cells in the
intestine of patients with Crohn&#146;s, and antibodies against IFN-g have been
shown to be effective in an animal model of intestinal inflammation resembling
Crohn&#146;s disease in humans. The disease causes inflammation and ulceration that
may affect the deepest layers of the lining of the digestive tract and can
cause deep ulcers and small sores called granulomas. Because it often affects
various portions of the digestive tract, Crohn&#146;s disease is likely to cause
vague symptoms, such as abdominal pain, fatigue, and weight loss. Children
with Crohn&#146;s disease may have the same symptoms as adults. In addition,
children may grow more slowly than normal and may go through puberty later than
expected. It is estimated that there may be up to 1,000,000 Americans with
IBD. Males and females appear to be affected equally. While Crohn&#146;s disease
afflicts people of all ages, it is primarily a disease of the young. Most cases
are diagnosed before age 30. Surgery becomes necessary in Crohn&#146;s disease when
medication can no longer control the symptoms, or when there is an intestinal
obstruction or other complication.
</FONT>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially from the statements made,
including risks associated with the success of clinical trials, the progress of
research and product development programs, the regulatory approval process,
competitive products, future capital requirements and the extent and breadth of
the Company&#146;s patent portfolio. The foregoing discussion of the effect of the
patent issued and pending involves risks and uncertainty, including the risks
that third parties may be successful in challenging the patent; or that granted
claims may be held invalid or interpreted differently by a court of law; or
that new technologies will be developed that are superior in treating the
diseases targeted by Advanced Biotherapy, Inc. See the Company&#146;s public filings
with the Securities and Exchange Commission for information about risks that
may affect the Company.
</FONT>
<P>
<HR size="1" width="18%" align="left" noshade>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
        <TD width="96%"><FONT size="2"><I>Contact:</I></FONT></TD>
</TR>
</TABLE>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced Biotherapy, Inc.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Edmond Buccellato, 818/883-6716, Ext. 2<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Keith Gregg, Business Development, Ext. 3<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E-mail: ed@advancedbiotherapy.com<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;keith@advancedbiotherapy.com<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Website: www.advancedbiotherapy.com
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
